Trigonal versus trigone-sparing intradetrusor injection of Botulinum Toxin-A for idiopathic detrusor overactivity

Submission date	Recruitment status	Prospectively registered
12/09/2010	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
04/10/2010	Completed	Results
Last Edited	Condition category	Individual participant data
04/10/2010	Urological and Genital Diseases	Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Mr Rustom Manecksha

Contact details

c/o Marjorie White-Flynn Lane Ward Adelaide & Meath Hospital Dublin Ireland 24

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

Study information

Scientific Title

Prospective randomised controlled trial comparing trigonal versus trigone-sparing intradetrusor injection of botulinum toxin-a for refractory idiopathic detrusor overactivity

Study objectives

Trigonal injections result in a better outcome

Ethics approval required

Old ethics approval format

Ethics approval(s)

Joint Hospitals Research Ethics Committee, Adelaide and Meath Hospital, Dublin approved on the 23rd October 2008 (ref: 2008/08/13)

Study design

Interventional randomised controlled study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Idiopathic detrusor overactivity

Interventions

Patients will be randomised to receive intradetrusor injections of 500u Botulinum Toxin-A (Dysport) sparing the trigone or including the trigone. 500u Dysport will be reconstituted with 20ml 0.9% saline. For trigone-sparing patients, 1 ml will be injected into 20 sites around the bladder sparing the trigone. For trigone-including patients, five 1 ml injections will be administered into the trigone and 15 injections around the bladder outside the trigone.

Intervention Type

Other

Phase

Phase III

Primary outcome measure

Overactive Bladder Symptom Score (OABSS) Questionnaire Total Score at baseline and at 6 weeks after injection (score range 7-28)

Secondary outcome measures

- 1. OABSS Questionnaire Total Score are 12 and 26 weeks (score range 7-28)
- 2. OABSS urgency subscale score at 6, 12 and 26 weeks (score range 4-16)
- 3. Urodynamic parameters at baseline and at 6 weeks
- 4. Specifically maximum detrusor pressure
- 5. Maximum cystometric capacity
- 6. Volume at first desire to void
- 7. Volume at urgent desire to void
- 8. Post void residual volume
- 9. Time to symptom recurrence

Overall study start date

15/09/2010

Completion date

15/11/2010

Eligibility

Key inclusion criteria

- 1. Male and female patients, 17 years and over
- 2. Urodynamic-confirmed detrusor overactivity
- 3. Have failed greater than or equal to 6 weeks anticholinergic therapy or discontinued therapy due to intolerability

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

22

Key exclusion criteria

- 1. Patients with any neurological condition or coagulopathies
- 2. Men with clinical or urodynamic evidence of bladder outflow obstruction
- 3. Patients with active urinary tract infection
- 4. Women with positive pregnancy test

Date of first enrolment

15/09/2010

Date of final enrolment

15/11/2010

Locations

Countries of recruitment

Ireland

Study participating centre c/o Marjorie White-Flynn

Dublin Ireland 24

Sponsor information

Organisation

Adelaide and Meath Hospital (Ireland)

Sponsor details

Department of Urology Dublin Ireland 24

Sponsor type

Hospital/treatment centre

ROR

https://ror.org/01fvmtt37

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Adelaide and Meath Hospital, Dublin (Ireland) - internal funding

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration